PharmaKit DX
Action PharmaKitDx: Comprehensive Pharmacogenomics via NGS The Action PharmaKitDx enables high-precision analysis of pharmacogenomics markers across 300 genes using NGS. it guides personalized therapy by detecting clinically relevant variants for over 130 drugs with unmatched accuracy. Note that this kit is for Research Use Only (RUO).
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
- NGS-Based Analysis
- 300 Pharmacogenomic Genes
- Blood Sample Ready (gDNA)
- High Sensitivity & Specificity
Precision Pharmacogenomics for Personalized Medicine
Action PharmaKitDx offers a comprehensive solution for the detection of pharmacogenomic variants across 300 genes relevant to drug response, dosing, and adverse reactions. Utilizing fully automated library preparation and hybridization capture, the kit sequences genomic regions with high coverage, enabling clinicians and molecular laboratories to make informed therapeutic decisions.
Clinical Relevance
The kit focuses on 20 main pharmacogenes, 12 secondary genes, and 303 candidate genes for research and emerging clinical applications. Variants detected include single nucleotide variants (SNVs), small insertions/deletions (INDELs), and copy number variations (CNVs), such as those in CYP2D6. Action PharmaKitDx facilitates pharmacogenomic-guided therapy for multiple drug classes, including cardiovascular agents, CNS drugs, immunosuppressants, antineoplastics, anti-infectives, and metabolism-related drugs.
Workflow and Technology
The workflow is optimized for the Illumina MiSeq platform, using the Magnis NGS Prep System for automated library preparation. The assay ensures high depth and coverage, with >99% sensitivity, specificity, repeatability, and reproducibility. Sample input requires only 100 ng of genomic DNA, typically extracted from peripheral blood.
Advancing Precision Medicine
By providing a broad, high-resolution view of genetic variants that influence drug response, the kit empowers molecular laboratories and clinicians to deliver personalized treatment strategies. Action PharmaKitDx represents a critical step toward safer, more effective, and individualized therapies in clinical pharmacogenomics.
Action PharmaKitDx has been designed to sequence more than 120,000 nucleotides across 300 genes. These genes have been divided into three groups (main, secondary, and candidate), according to their relevance in clinical practice.
There are pecific dosing strategies for variants in main and secondary genes (32) for more than 130 drugs.
- Main genes (20 genes): ABCG2, CACNA1S, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A5, CYP4F2, DPYD, F5, G6PD, HLA-A, HLA-B, IFNL3, NUDT15, RYR1, SLCO1B1, TPMT, UGT1A1, VKORC1.
- Secondary genes (12 genes): ABCC3, CALU, COMT, CYP1A2, CYP2C18, CYP3A4, GGCX, NAT1, NAT2, RARG, SLC28A3, UGT1A6.
- Candidate genes (303 genes): Regions awaiting clinical validation and/or of interest for research projects. For specific information, contact to our clinical team.
The kit is equipped with reagents for 16 reactions, including:
- KIT-Gen Master Mix: Includes oligonucleotides, fluorescent hydrolysis probes (FAM and VIC), and water for amplifying and detecting the alleles under scrutiny.
- General Master Mix: PCR Master Mix containing nucleotides, MgCl2, enzyme, and buffer for real-time PCR.
- Positive Control: A control that simultaneously amplifies the mutated and wild-type alleles (simulating a heterozygous sample).
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Instructions for Use
MSDS PharmaKitDx
Frequently paired with this kit
Other assays and instruments lab teams add alongside the PharmaKit DX.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
